期刊
BRITISH JOURNAL OF HAEMATOLOGY
卷 171, 期 4, 页码 625-630出版社
WILEY-BLACKWELL
DOI: 10.1111/bjh.13622
关键词
immune thrombocytopenia purpura; platelets; mycophenolate mofetil
类别
资金
- British Heart Foundation [FS/10/013/28073] Funding Source: Medline
- Medical Research Council [G0800671] Funding Source: Medline
- MRC [G0800671] Funding Source: UKRI
- British Heart Foundation [FS/10/013/28073] Funding Source: researchfish
- Medical Research Council [G0800671] Funding Source: researchfish
Severe immune thrombocytopenia purpura (ITP) presents a clinical challenge. Second-line treatment options are variable without a precise protocol. We present 46 severe ITP patients treated with mycophenolate mofetil (MMF), retrospectively identified from three London teaching hospitals. Data was collected on patient demographics, co-morbidities and previous treatment strategies. Our key interest was whether there was a sustained response in platelet count to MMF. Patients included 27 males and 19 females whose ages ranged from 19 to 93years old (median 525years). Twenty-nine had primary ITP and 17 had secondary ITP, a third of whom had viral-associated disease. The standard dose of MMF was 1g/day. Twenty-four patients (52%) responded with 15 (33%) achieving a complete response. No active viral-associated ITP patients demonstrated a response to MMF, although numbers were small (n=4). We were not able to demonstrate a difference between responders and non-responders based on gender, age, previous therapies or time since diagnosis of ITP. Three of four previously splenectomized patients responded, two achieving complete response. We conclude that MMF is a useful steroid-sparing immunosuppressant to be considered in the second-line or later treatment of ITP.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据